Purpose of the Review Cannabis is the most commonly used illicit substance worldwide. In recent decades, highly concentrated products have flooded the market, and prevalence rates have increased. Gender differences exist in cannabis use, as men have higher prevalence of both cannabis use and cannabis use disorder (CUD), while women progress more rapidly from first use to CUD. This paper reviews findings from preclinical and human studies examining the sex-specific neurobiological underpinnings of cannabis use and CUD and associations with psychiatric symptoms. Recent Findings Sex differences exist in the endocannabinoid system, in cannabis exposure effects on brain structure and function, and in the co-occurrence of cannabis use with symptoms of anxiety, depression, and schizophrenia. In female cannabis users, anxiety symptoms correlate with larger amygdala volume, and social anxiety disorder symptoms correlate with CUD symptoms. Female cannabis users are reported to be especially vulnerable to earlier onset of schizophrenia, and mixed trends emerge in the correlation of depressive symptoms with cannabis exposure in females and males. Summary As the prevalence of cannabis use may continue to increase given the shifting policy landscape regarding marijuana laws, understanding the neurobiological mechanisms of cannabis exposure in females and males is key. Examining these mechanisms may help inform future research on sex-specific pharmacological and behavioral interventions for women and men with high-risk cannabis use, comorbid psychiatric disease, and CUD.
Introduction
Cannabis (sativa, indica) is the most commonly used illicit substance worldwide [1] . In the USA, the prevalence of past year cannabis use among individuals aged 12 or older increased from 10.9% in 2008-2009 to 13 .4% in 2014-2015 [2] . This increase in prevalence may be due in part to increases in illicit use of cannabis in states with medical marijuana laws [3, 4] , as well as decreases in perceptions of risks associated with cannabis [5] . Not only has the prevalence of cannabis use increased but so too the concentrations of Δ 9 -tetrahydrocannabinol (THC; the primary psychoactive compound). THC levels in a typical cannabis strain have doubled from 2006 to 2014 [6] . Given the prevalence of cannabis use, the rapidly changing policy landscape, and the proliferation of highpotency products, it is important to investigate the mechanisms underlying cannabis use disorder (CUD), the DSM-V condition characterized by cannabis abuse and dependence.
According to the 2015 National Survey on Drug Use and Health, 2.6% of adolescents (aged 12-17) and 1.4% of adults (aged 18+) met DSM-IV criteria for past year cannabis dependence or abuse, though no gender breakdown was noted [7] . For perspective, 2.5% of adolescents and 6.2% of adults met criteria for past year alcohol use disorder [7] . In a second national study with gender-specific breakdown of CUD, 2.5% of adults met DSM-V criteria for past year CUD, with prevalence in men (3.5%) more than double that in women (1.7%) [8] . In a sample of adults diagnosed with CUD at some point in their lifetime (i.e., with lifetime CUD), men, relative to women, met a greater number of cannabis abuse criteria [9] . However, in comparison to men, women who use cannabis have been shown to more likely exhibit a "telescoping effect," characterized by faster progression from first use to CUD [9, 10] . Further, women have reported higher ratings of abuserelated subjective effects in response to cannabis use compared to men [11•] , which may contribute to a more rapid progression to dependence. Additionally, women with lifetime CUD were more likely than men to have psychiatric comorbidities including bipolar I and II, alcohol use disorder, nicotine dependence, and several externalizing disorders, after adjusting for sociodemographic measures and prevalence of psychiatric disorders [9] . Both the rapid progression from first use to CUD and the increased risk for psychiatric comorbidity conferred by CUD in women implicate biological differences underlying the development and maintenance of CUD. This may render women more vulnerable to psychiatric disability.
The purpose of this review, therefore, is to examine potential neurobiological mechanisms of sex differences in cannabis exposure and dependence. Sex differences in the endocannabinoid system and exogenous THC effects on physiology will be reviewed, followed by sex-specific effects of cannabis exposure during the vulnerable period of adolescence. Preclinical and human studies examining sex differences in cannabis exposure effects during adulthood will then be reviewed, followed by sex differences in cannabis use comorbidity with psychiatric symptomatology related to anxiety, depression, and schizophrenia. Overall, the aim of this review is to yield a better understanding of the neurobiological sex differences that may underlie sex-specific vulnerabilities to, and features of, cannabis dependence.
Method
Using PubMed and Google Scholar, we conducted a literature review of peer-reviewed articles published between January 2010 and April 2017. We used the following search terms in various combinations: "cannab*," "sex," "gender," "THC," "marijuana," "female," "sex differences," "schizophrenia," "depression," and "anxiety." Additional papers are cited to provide context for hypotheses investigated in more recent literature. In accordance with definitions set by the Institute of Medicine, the term "gender" is applied to human studies and the term "sex" is applied to animal studies, as well as joint analyses of preclinical and clinical data, in this review.
Sex Differences in the Endocannabinoid System
Endocannabinoid System Biology The neurobiology of the endocannabinoid system has previously been reviewed [12] [13] [14] [15] . Commonly used terms are defined in Table 1 . Briefly, the cannabinoid-1 receptor (CB1-R) is the primary mediator of cannabinoid signaling in the central nervous system [16, 17] and is accompanied in lower levels by cannabinoid-2 receptors (CB2-R) [18, 19] . Cannabinoid receptors (CB-Rs) are activated by the endogenous ligands Na r a c h i d o n o y l e t h a n o l a m i n e ( A E A ) [ 2 0 ] and 2-arachidonoylglycerol (2-AG) [21] [22] [23] , as well as exogenous ligands including THC and synthetic cannabinoids [24] . CB1-Rs are widely distributed in brain regions including the frontal cortex, hippocampus, cerebellum, hypothalamus, basal ganglia, and reward circuit areas such as the ventral tegmental area and nucleus accumbens [14] . CB1-Rs are presynaptic terminal bound G-protein-coupled receptors (GPCRs) that, when activated, trigger G i/O -protein coupling and intracellular events that ultimately reduce intracellular Ca 2+ and K + concentration and inhibit neurotransmitter release [14] . THC has been shown to induce dopamine release in nucleus accumbens [25, 26] , which is thought to underlie the rewarding effects of most drugs of abuse [27] . In addition, cannabinoids are shown to decrease GABA-mediated inhibitory transmission [28] , modulate NMDA and AMPA receptor-mediated excitatory transmission [29] , and exert reinforcing effects via CB1-R activation in reward areas mediated by cholinergic and opioidergic systems [30] .
Sex Differences in Cannabinoid Receptor Expression
The relationship of sex and the cannabinoid receptor system has long been studied [31] [32] [33] . CB1-R mRNA transcript levels have been reported to be higher in anterior pituitary [34] and lower in the cerebellum [35] , prefrontal cortex, amygdala, and hippocampus [36] in males, compared to females. Greater CB1-R density has been observed in male animals in the mesencephalon [37] , hypothalamus [38] , hippocampus [38, 39] , and prefrontal cortex [40• ], compared to females, with mixed results in the amygdala [38, 40•] , though other evidence suggests greater widespread CB1-R density in females, compared to males [41] . In humans, in vivo positron emission tomography (PET) imaging demonstrated that CB1-R availability is lower in healthy men compared to healthy women in most regions [42•, 43] , though some evidence indicates higher CB1-R availability in men, compared to women, in the cortico-striatal-thalamic-cortical circuit [44] . Conflicting evidence may, in part, be attributed to differences in experimental design, specifically in CB1-R-specific radioligand as well as outcome measure. Interestingly, CB1-R availability has been shown to increase with age in women, but not men, in the basal ganglia, limbic regions, lateral temporal cortex, and hippocampus [44] . Hormones appear to play a role in these differences since ovariectomized female rats exhibit higher CB1-R expression in the frontal cortex [40•] and hippocampus [38] compared to intact females, though mixed trends emerge in the amygdala [38, 40•] . Sex differences here, and throughout the remainder of this review, with a focus on neurobiological changes in the striatum, hippocampus, amygdala, and frontal cortex, are reported in Table 2 .
Sex Differences in Cannabinoid Physiological Effects and Metabolism Prior to examining sex differences in cannabis exposure-related behavioral, structural, and functional phenomena, it is important to understand how cannabinoids sexspecifically impact physiology. In humans, cannabis exposure increases heart rate in both women and men [67, 68] , but to a lesser extent in women [68, 69, 70•] . Women have reported greater sedative effects [68] and dizziness [71] compared to men in response to cannabis, though the amount of cannabis per body weight was not adjusted. Women also responded to cannabis extract with significantly greater fatigue, drowsiness, and psychomotor suppression compared to women treated with placebo [72] .
These sex-dependent physiological effects may, in part, be attributed to sex differences in cannabinoid metabolism. In one study, THC metabolism in female rats yielded the primary metabolite 11-OH-THC only, compared to multiple metabolites in males [73] . Brain levels of metabolite 11-OH-THC were higher in THC-exposed female rats compared to male rats [74, 75•] , yet plasma THC levels have been shown to be both higher [76] and lower [77] in THC-exposed women, compared to men. This is important, as the typical THC content in cannabis continues to increase over time [6] , and may contribute to sex-specific trajectories to dependence. Together, these differences suggest that women may experience more depressive-like symptoms from cannabis exposure, including sedation and psychomotor suppression, which may help inform the following findings on sex differences in cannabis use-related behaviors.
Adolescent Cannabinoid Exposure Impacts Adulthood: Preclinical Studies
Cannabis use is typically initiated in adolescence [9] , a period marked by robust behavioral and brain development. Cannabinoid use in adolescence has profound effects on cannabis use and related changes in biology and behavior in adulthood [78•, 79] , in a sex-dependent manner [80, 81, 82•] . The majority of the literature examining these effects at the neurobiological level is in animal models, with some investigation in humans.
Adolescent Cannabinoid Exposure Has Sex-Specific Effects on CB1-Rs in Adulthood Preclinical cannabinoid exposure in adolescence largely induces a sex-independent, widespread reduction in CB1-R density [41, 47, 83, 84 •], although enhancement in the hippocampus in female animals [45, 46•, 48] , and striatum in both sexes [46• ], has been observed. Chronic THC exposure during adolescence led to a reduction in CB1-R density in the amygdala [47] , caudate, putamen, nucleus accumbens, and substantia nigra [41] of adult male rats. In THC-exposed female rats, reductions were also observed in these regions, as well as ventral tegmental [41, 47] , prefrontal cortex, globus pallidus, and hypothalamus [41] . CB1-R reduction was observed in the hippocampus in females and males, though in more hippocampal subregions in females [84•] . Additionally, THC exposure reduces striatal CB1-R density in female rats, independent of ovarian hormone status [49] . Adolescent THC exposure has been shown to lead to sex-dependent reduction in agonist-induced activation of CB1-Rs in adulthood, specific to the hippocampus, in males, and to the amygdala and nucleus accumbens, in females [47] . Deficits in cannabinoid signaling in these brain regions, therefore, could impact emotion and reward regulation.
Adolescent Cannabinoid Exposure Has Sex-Specific Effects on Other Receptor Systems in Adulthood
Cannabinoid exposure in adolescence impacts the glutamate, GABA, and dopaminergic systems in adulthood. In the glutamate system, adult female rats, with cannabinoid exposure in adolescence, showed reduced NMDA receptor density [41, 52] [41] , increased dopamine D2 receptor density in the prefrontal cortex of males [41] , and reduced dopamine D2 receptor density in the hippocampus of both sexes [55] . In humans, adult cannabis users with onset in adolescence have shown no difference in striatal dopamine D2/D3 receptor availability compared to healthy controls [85, 86] but do show blunted dopamine transmission compared to healthy controls [87•] . Sex differences, however, have not been examined in these imaging studies.
Adolescent Cannabinoid Exposure Has Sex-Specific Effects on Cannabinoid Reinforcing Efficacy in Adulthood Preclinical self-administration paradigms can be used to examine the reinforcing efficacy of drugs of abuse by modeling acquisition and maintenance of drug use [88] , including cannabinoid use [89, 90•] . Male rats that selfadminister cannabinoids in adolescence have exhibited faster and more robust self-administration in adulthood compared to controls [56] . They have also shown a blunted cannabinoidinduced dopamine release in the ventral tegmental area and nucleus accumbens, compared to controls, suggesting a longlasting deficit in the dopaminergic circuitry [56] . One limitation, however, is that no similar study has been conducted in females to allow for exploration of sex differences. In all, further investigation into female-specific, adolescent cannabinoid exposure effects on THC self-administration and reinforcing efficacy in adulthood is needed.
Adolescent Cannabis Exposure Effects on Adolescence and Adulthood: Human Studies
Similar to preclinical studies, several human studies reveal adolescent cannabis use effects on the brain [91, 92] . Few, however, include female cannabis users and, in those that do, analysis with gender as a main effect is either unreported or unattainable due to statistical limitations [93] [94] [95] . Thus, in contrast to the previous exclusive focus on adolescent cannabis use effects on the adult brain, this section's focus is on studies with analyses of gender differences in adolescent cannabis use effects on brain structure and function during adolescence as well as adulthood.
Gender Differences in Human Adolescent Cannabis Exposure on Brain Structure and Function in Adolescence In one study, female cannabis using adolescents had significantly larger right amygdalae compared to female nonusers, an effect not observed in males [66] . During late adolescence and young adulthood, both female and male cannabis users had smaller gray matter volumes than nonusers in decision-making and executive function areas of the brain, i.e., the medial orbitofrontal and inferior parietal cortices [96] . In adolescents with substance use disorder and comorbid conduct problems, many of whom were cannabis dependent, females had less cortical thickness in parts of the anterior cingulate cortex and medial orbitofrontal cortex compared to female controls [58], with no similar effect observed in males [97] . In a separate set of studies, comparably characterized subjects had significantly less gray matter volume than gender-matched controls in left and right dorsolateral prefrontal cortex, in males [60] and females [59], respectively. Bilateral cerebellum was also smaller in male users compared to male controls, and in female users, less gray matter volume was observed in several additional frontal and parietal regions. Together, this evidence indicates gender-specific differences in adolescent cannabinoid exposure on executive function and decision-making areas of the brain, which may inform genderspecific cognitive effects of cannabis as well as optimal treatment strategies for cannabis dependence.
Gender Differences in Human Adolescent Cannabinoid Exposure on Brain Structure and Function in Adulthood
In one study, a mixed-gender adult population with adolescent-onset (<17 years) cannabis use exhibited less gray matter and more white matter, as a percentage of whole brain volume, compared to young adult-onset users [98] . In a second study, adolescent-onset users (<16 years) showed greater brain activity, measured by blood-oxygen-leveldependent (BOLD) functional magnetic resonance imaging (fMRI), in dorsal striatum in response to cannabis cues, compared to young adult-onset users [99] . Although not gender linked, this may be driven by the significantly more women comprising the adolescent-onset group, though further analysis is necessary [99] . Independent of gender, smaller orbitofrontal cortex volume at age 12 was associated with early cannabis use, highlighting the role of decision-making in drug-taking behaviors [100] . These findings suggest that regardless of gender, cannabis use leads to a reduction in brain volume in adulthood, which may render early cannabis users vulnerable to disease in adulthood, as well as deficits in cognition and behavior, though further investigation is needed to evaluate these implications.
Sex Differences in the Rewarding Properties of Cannabinoids
Preclinical Cannabinoid Self-Administration Preclinical cannabinoid self-administration in adulthood is characterized by an inverted U-shape dose-effect curve that has been demonstrated with CB1-R agonists and THC, although some studies report insufficient reinforcement by THC [101] [102] [103] . Cannabinoid self-administration has led to enhanced extracellular dopamine levels in the nucleus accumbens [104] [105] [106] and is modulated by CB1-R [102, [106] [107] [108] , opioidergic [108] [109] [110] [111] [112] , and adenosine 2A receptor [113, 114] antagonism and by anabolic steroid hormone treatment [115] . Although sex differences in drug self-administration in general have been reported [116] , sex differences tend not to emerge in the cannabinoid literature due to largely male samples. Only one group has explored cannabinoid self-administration in females, and significantly faster acquisition, as well as more robust maintenance, was observed in female rats compared to male rats [117] . Sex-dependent differences do emerge irrespective of self-administration, such as enhanced sensitivity to THC-induced taste avoidance [118] and THC discrimination [119•] in female rats, but further investigation must be done to systematically examine preclinical sex differences in cannabinoid reinforcement.
Human Cannabinoid Self-Administration A small but growing gender-inclusive literature exists on human studies of cannabinoid self-administration [120] . One study of a male cannabis-using sample found that participants exhibited preference for and choice of active cannabis over placebo [121] .
Other work among male cannabis users has demonstrated increased subjective intoxication, heart rate, and "liking" of drug as a function of THC potency in self-administered cannabis [122, 123] . One study including a female cannabisusing sample found that participants similarly exhibited increased intoxication and elevated pulse rate after cannabis use [124] . Further, acute cannabis self-administration by females with moderate cannabis use enhanced confusion, vigor, elation, and friendliness, but prolonged self-administration reduced these feelings [124] . Increased cannabis use during the premenstrual phase of the ovulatory cycle has been reported and was correlated with significantly greater depressive features [125] . However, no consistently significant relationship between menstrual cycle phase and modulation of cannabis self-administration has been observed [125, 126] . Genderinclusive studies report similar findings and additionally demonstrate modulation of self-administration by treatment with oral THC [127, 128] , oral cannabidiol [129] , and an opioid receptor antagonist [130•] . These studies, however, either lack adequate power to test for gender differences, or do not report analyses of gender differences.
Cannabis-Induced Subjective Effects Cannabis and THC alone typically increase subjective "high" ratings in both women and men, but studies conflict as to whether genderdependent differences exist. One study demonstrated a greater increase in cannabis-induced "high" in female cannabis users compared to males [131] , yet another study in nonusers exposed to cannabis reported greater increases in "high" ratings in males compared to females [132] . Conflicting evidence may be due to smoking status differences in the populations of each study, as well as differences in THC capsule dosing indicated in each experimental design. Cannabis-induced increases in "good" and "take again" ratings were shown to be enhanced in women compared to men [11] , but also shown to be gender independent [70] . In a female-only study, cannabis exposure increased ratings of confusion among regular and intermittent cannabis users, although this effect was stronger among intermittent users [67] . Other female-only work has demonstrated increased psychiatrist-rated scores of poor affective response and emotional withdrawal in drug-naive females [72] .
Cannabis Cue Reactivity and Cue-Induced Craving Gender differences emerge less in the magnitude of cue reactivity, but more in the underlying neural mechanism. For example, prior work has shown that greater cannabis use in both women and men is associated with greater cannabis cue reactivity [133•] . Women, compared to men, exhibited larger cueinduced enhancement of event-related potential signals, specifically in P300 amplitude, shown to be enhanced in many studies of drug-related cue reactivity, and in early posterior negativity amplitude, shown to be sensitive to motivationrelated stimuli [133•] . In cannabis users exposed to subliminally presented cannabis cues, men had preferential BOLD signal response in the left striatum and left lateral orbitofrontal cortex, yet women preferentially responded in the striatum, left hippocampus, and amygdala [64•] . Some groups have examined cue-reactivity associations with risk genes CNR1 and FAAH, but gender differences were either not found [134] or not further analyzed [135] . Cannabis cue-induced craving has been reported in both men and women [136] . Further, in a mostly female sample of cannabis users, cueinduced craving was correlated with occipital cortex, parahippocampal gyrus, thalamus, hippocampus, superior temporal pole, and middle occipital gyrus activation [137] ; however, within-group gender differences were not reported. Volume of ventricular cerebrospinal fluid was reported to be lower in cannabis users, compared to controls, without varying by gender [141] . In one recent study, dependent cannabis users, compared to nondependent users, had significantly smaller volumes in medial and lateral orbitofrontal cortex, the latter effect being more pronounced in women than men [57•]. Overall, more structural neuroimaging of gender differences in current cannabis users is needed to elucidate consistent patterns of change in brain structure, specific to female and male cannabis users.
Gender Differences in Brain Function Similarly, several functional neuroimaging studies inclusive of women cannabis users lack statistical power or do not report gender differences [85, 87•, 142, 143•] . Of those that examine gender differences, mixed results emerge. In an electroencephalogram study, female cannabis users showed altered visual processing as indicated by reduced visual steady-state evoked potential spectral power at low-frequency stimulation compared to female controls, an effect not observed in males [144] . In adulthood, males who began using cannabis during adolescence had significantly higher cerebral blood flow compared to those who initiated use as young adults, though females showed no significant difference [98] . Female cannabis users did, however, exhibit region-specific lower levels of glucose metabolism in left superior frontal gyrus, right occipital cortex, and right anterior cingulate cortex compared to female controls, an effect not observed in men [63•]. Further, female cannabis users, but not male cannabis users, had blunted methylphenidate-induced enhancement of glucose metabolism in the cerebellum, medial frontal gyrus, pons, hippocampus, thalamus, and midbrain compared to female controls [63•]. In a mixed group of adolescents and young adults, female cannabis users, in the dorsal striatum, had lower scaled levels of glutamate and glutamine compared to female controls, an effect not observed in males, as well as higher myoinositol levels, a glial marker observed in high concentrations in early dementia, compared to female controls and all males [54] .
Sex Differences in Cannabis Use Comorbidity with Psychiatric Symptoms
Comorbidity with Anxiety Symptoms Female cannabis users have self-reported significantly higher levels of anxiety problems during withdrawal compared to male cannabis users [145] . Females seeking treatment for cannabis dependence, particularly in late adolescence and middle adulthood, have also shown higher rates of anxiety compared to males [146•] . Social anxiety disorder symptoms were correlated with cannabis use disorder symptoms in women but not men [147] . This relationship appears to be nuanced, however, by reported motives for cannabis use. Specifically, social anxiety in males has been associated with cannabis use motives related to conformity (e.g., to fit in with a group I like) and coping (e.g., to forget my worries) [148] . By contrast, in females, social anxiety has been associated with social-based motives (e.g., to enjoy a party) to use cannabis [148] . It is unclear what mechanism may contribute to these differences, although the amygdala has been implicated [66] . Specifically, as detailed earlier, female cannabis users had larger right amygdala volumes compared to female non-users, an effect not observed in males [66] . Further, in female cannabis users, larger right amygdala volume was associated with worse anxiety and depression symptomatology, yet the opposite trend was observed in female controls and males [66] . While gender differences have emerged with respect to anxiety symptoms and motives, additional work is needed to elucidate gender differences in mechanisms related to cannabis motives and anxiety. Preclinical investigation has begun to address this gap by exploring potential mechanistic explanations for sexdependent associations between cannabinoid exposure and anxiety. Some groups reported no effects of adolescent cannabinoid exposure in rodents on anxiety in adolescence [51] or adulthood [47, 53•] , and others reported a male-specific reduction in anxiety or anxious behavior with cannabinoid exposure [50•, 149, 150] . Adequate comparison of conflicting results is limited, however, as these studies vary in their administered cannabinoid (i.e., CP 55,940 vs. THC) which may impact potency of effect at the receptor level. Female rats have similarly shown mixed anxiety effects to cannabinoid exposure [151] , and cannabinoid-induced enhancement of social anxiety, specifically, has been noted in females [152] and males [149] . CB1-R activity may mediate these effects, as global knockout of this receptor expression increased anxiety in male mice compared to controls, an effect not observed in female mice [153] . Further, specific CB1-R knockout on cortical glutamatergic and forebrain GABAergic neurons was associated with reduction in social interaction in male mice, with no females tested in this experiment [65] .
Comorbidity with Depressive Symptoms Evidence for gender-specific associations of depression and cannabis use is mixed. Cross-sectional work has indicated a stronger association between cannabis use and depression in females, compared to males [154] , but longitudinal work indicates a strong association over time in both females [155] and males [156•] . Adolescent cannabis use has been shown to be predictive of depression in male and female adolescent students [157] . Adolescent cannabis use, however, did not significantly predict young adult depression [158] . Studies on factors associated with depression have shown that in comparison to males, female cannabis-using adolescents are at a greater risk for suicide [146•] , as well as self-harm as a function of cannabis use [159] . In a longitudinal study, heavy cannabis use in males, but not females, was significantly associated with increased odds of later suicidal ideation [160•] . In contrast, past suicidality in females, but not males, was associated with initiation of cannabis use [160•] . Another study showed that cannabis craving was correlated with self-reported depression, and when depression was held as a covariate, greater craving scores emerged for males compared to females [161] . Further, cannabis-dependent males in a separate study exhibited greater feelings of "down" in response to cannabis cues compared to females [162•] , and as previously mentioned, cannabisnaive females showed increased, cannabis-induced, psychiatrist-rated poor affective response and emotional withdrawal [72] . While the literature is mixed, it seems apparent that gender differences exist, and additional work is needed to understand the mechanisms contributing to these patterns.
Aside from the aforementioned evidence for increased anxiety and depression symptomatology with right amygdala volume in female cannabis users [66] , we are not aware of further mechanistic understanding of gender differences in cannabis use associated with depression. Investigations in mixedgender populations have indicated that smaller white matter volume is associated with greater depression symptomatology in adolescent cannabis users [163] . Cannabis users had more cerebellar gray matter volume compared to nonusers, but this was not associated with depressive symptoms [61] . Preclinical studies have indicated that adolescent THC exposure elevates depressive-like behavior in adulthood in female rats [47, 164•] but not male rats [47] . Cannabinoid exposure in males, in contrast, has been shown to decrease depressive-like behavior [50•, 165] . Conflicting evidence does exist, however, as elevated depressive symptoms in both sexes [41] , or no effects in males [53•], have been reported. Altogether, cannabis use correlates with several measures of depression in humans, cannabinoid exposure has mixed effects on depressive symptoms in preclinical animal models, and varied sex-specific associations between cannabis use and depression emerge across studies, necessitating further inclusion of females in studies of depression in cannabis use.
Comorbidity with Schizophrenia and Psychotic
Symptoms Cannabis use has been implicated in the onset of schizophrenia and psychotic symptoms [166] . Men have been shown to have an earlier onset of schizophrenia than women [167, 168] , and age of onset of in cannabis users is shown to be earlier than nonusers [168, 169•] . Though cannabis use was shown to be more prevalent among men with schizophrenia relative to women [170•] , female cannabis users are reported to be at higher risk of early onset of psychosis compared to male users [171] . Possible genetic factors involved in gender-specific differences in age of psychosis onset have been reported [167, 172•] . Neuroimaging studies suggest that individuals with schizophrenia who use cannabis have an altered subcortical region shape [173] and have less gray matter in the anterior cingulate [174] and posterior cingulate cortex [175] and more widespread regions in the brain [176, 177] compared to non-using controls with schizophrenia, though gender difference analysis is not reported or not observed as in one case [174] . In rodents, psychotic-like behavior is modeled by diminished prepulse inhibition, related to deficits in sensorimotor gating and attention in people with schizophrenia, and enhanced acoustic startle reflex [178] . THC exposure significantly reduced prepulse inhibition in female rats [178] and enhanced acoustic startle activity in both males and females [179•] . These findings highlight the potential mechanisms that may contribute to sex differences in the impact of cannabis on schizophrenia and psychosis.
Conclusion
Cannabis is the most commonly used illicit substance, and as it becomes increasingly accessible, it is critical to understand how the neurobiological underpinnings of cannabis addiction differ between women and men. Sex differences exist in the endogenous cannabinoid receptor system, cannabis metabolism, and the subjective effects of cannabis. There are not yet studies, however, reporting consistent differences in brain structure or function between female and male cannabis users. More commonly, gender differences emerge in how female or male cannabis users compare with their same-gender nonuser counterparts. This is evident structurally, with less gray matter volume and cortical thickness observed, and functionally, with blunted methylphenidate-induced enhancement of glucose metabolism in the hippocampus and frontal cortex, in female cannabis users compared to female nonusers.
Gender differences emerge in behavioral and neurobiological profiles of cannabis users with comorbid symptomatology related to anxiety, depression, and schizophrenia. Social anxiety disorder symptoms correlated with CUD symptoms in women, but not men, and anxiety symptoms correlated with larger amygdala volume in female cannabis users. Female cannabis users are shown to be especially vulnerable to earlier onset of schizophrenia, compared to male cannabis users, but it is unclear what neurobiological sex differences contribute to this phenomenon and more studies are necessary. Lastly, in depression, mixed trends emerge in support of enhanced depressive symptoms with cannabis use in both females and males. Amygdala is again implicated in females, but further investigation is required.
Taken together, the studies reviewed here that examine gender differences in neurobiological mechanisms of cannabis use yield mixed results, and thus, more evidence is needed to fully understand how cannabis use differentially impacts females and males. Differences in experimental design of preclinical studies may contribute to conflicting findings, such as differences in cannabinoid used to antagonize the CB1-R system or in paradigms used to evaluate reinforcing efficacy of cannabis. Similarly, differences in neuroimaging parameters, cannabis dosing, and type of cannabis administration in clinical studies may produce competing results obtained to answer the same research question. Further, many studies still do not include female subjects, and in those that do, gender is not often discussed as a variable of interest. This makes it difficult to identify promising avenues for investigating gender differences in future research.
In future studies, it is important to actively include female and male subjects, and to systematically examine sex differences, with adequate power, in both preclinical and clinical samples. The majority of clinical studies on gender differences in cannabis use either administer cannabis to assess subjective effects without measures of neural activity or examine neural activity in cannabis users without active cannabis administration. To fully understand gender differences in cannabis use, it is critical that new studies bridge the gap between these two paradigms and incorporate active cannabis administration into neuroimaging studies. Acute effects of cannabis use, both behaviorally and neurobiologically, could then be identified and analyzed for differences between women and men. Examination of sex differences and related neurobiological mechanisms is critical to inform future research on genderspecific pharmacological and behavioral interventions for women and men with high-risk cannabis use, comorbid psychiatric disease, and CUD.
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